Vascepa is a prescription drug used to lower triglyceride levels in adults with severe hypertriglyceridemia. It contains the active ingredient icosapent ethyl and is manufactured by Amarin Corporation. According to the sources provided, Vascepa discounts are being discontinued due to the expiration of its patent protection [3].

Vascepa's patent was set to expire in 2030, but a court ruling in March 2020 invalidated six of its patents, allowing generic versions of the drug to be produced [3]. This ruling was upheld in August 2020, and Amarin has since announced that it will no longer offer discounts for Vascepa [3].

The Vascepa Savings Card program, which offered eligible patients a discount on their co-payments for the drug, will be discontinued as of December 31, 2020 [2]. Patients who currently use the savings card will be able to continue using it until that date, but no new patients will be enrolled in the program [2].

In summary, Vascepa discounts are being discontinued due to the expiration of its patent protection and the availability of generic versions of the drug. The Vascepa Savings Card program will be discontinued at the end of 2020.

Sources:
[2] https://www.vascepa.com/getting-started/vascepa-savings/
[3] https://www.fiercepharma.com/marketing/it-s-confirmed-amarin-loses-patent-appeal-protecting-blockbuster-hopeful-vascepa-from
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA